TY - JOUR
T1 - Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19
AU - McKenzie, Robin
AU - Porter, Chad K.
AU - Cantrell, Joyce A.
AU - DeNearing, Barbara
AU - O'Dowd, Aisling
AU - Grahek, Shannon L.
AU - Sincock, Stephanie A.
AU - Woods, Colleen
AU - Sebeny, Peter
AU - Sack, David A.
AU - Tribble, David R.
AU - Bourgeois, A. Louis
AU - Savarino, Stephen J.
N1 - Funding Information:
This work was supported by the Peer-Reviewed Medical Research Program (W81XWH-04-1-0067 to SJS) and by Johns Hopkins University School of Medicine General Clinical Research Center (M01-RR00052 from the National Center for Research Resources, National Institutes of Health).
PY - 2011/7/1
Y1 - 2011/7/1
N2 - Human challenges with enterotoxigenic Escherichia coli (ETEC) have broadened our understanding of this important enteropathogen. We report findings from the first challenge studies using ETEC-expressing colonization factor fimbria CS17 and CS19. LSN03-016011/A (LT, CS17) elicited a dose-dependent effect, with the upper dose (6 × 109 organisms) causing diarrhea in 88% of recipients. WS0115A (LTSTp, CS19) also showed a dose response, with a 44% diarrhea rate at 9 × 109 organisms. Both strains elicited homologous antifimbrial and anti-LT antibody seroconversion. These studies establish the relative pathogenicity of ETEC expressing newer class 5 fimbriae and suggest suitability of the LT|CS17-ETEC challenge model for interventional trials.
AB - Human challenges with enterotoxigenic Escherichia coli (ETEC) have broadened our understanding of this important enteropathogen. We report findings from the first challenge studies using ETEC-expressing colonization factor fimbria CS17 and CS19. LSN03-016011/A (LT, CS17) elicited a dose-dependent effect, with the upper dose (6 × 109 organisms) causing diarrhea in 88% of recipients. WS0115A (LTSTp, CS19) also showed a dose response, with a 44% diarrhea rate at 9 × 109 organisms. Both strains elicited homologous antifimbrial and anti-LT antibody seroconversion. These studies establish the relative pathogenicity of ETEC expressing newer class 5 fimbriae and suggest suitability of the LT|CS17-ETEC challenge model for interventional trials.
UR - http://www.scopus.com/inward/record.url?scp=79957931197&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir220
DO - 10.1093/infdis/jir220
M3 - Article
C2 - 21628659
AN - SCOPUS:79957931197
SN - 0022-1899
VL - 204
SP - 60
EP - 64
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -